Heraeus PALACOS R pro bone cement recalled for ampoule breakage
Heraeus Medical is recalling PALACOS R pro 40 and R pro 80 bone cement products because the ampoules (small sealed containers) inside the mixing systems may not break properly during use. When ampoules fail to break, the bone cement cannot be prepared correctly and cannot be used during surgery.
From the FDA notice · Read the official notice ↗
What to do
- Stop using any PALACOS R pro 40 or R pro 80 units with lot codes matching UDI-DI 04260102136120 or 04260102136151
- Contact Heraeus Medical or your surgical supplier for instructions on how to return or dispose of affected units
- Consult with your facility's surgical team if this product was recently used in procedures
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Brand Name: PALACOS Product Name: PALACOS R pro 40; PALACOS R pro 80 Model/Catalog Number: 5081286; 5081287 Software Version: N/A Product Description: Radiopaque, poly(methyl methacrylate)-based (PMMA) bone cement, pre-filled into a mixing and application system, suitable for use with or without vacuum (ready to mix). Component: N/A
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
This recall covers 4 products — see all of them.
Details
- Illnesses reported
- None reported
- Manufactured in
- Philipp-Reis-Str. 8, Wehrheim, Germany
- Classification
- Class II
- Recall number
- Z-1080-2026
In the FDA's words
- Description
- Brand Name: PALACOS Product Name: PALACOS R pro 40; PALACOS R pro 80 Model/Catalog Number: 5081286; 5081287 Software Version: N/A Product Description: Radiopaque, poly(methyl methacrylate)-based (PMMA) bone cement, pre-filled into a mixing and application system, suitable for use with or without vacuum (ready to mix). Component: N/A increase of complaints regarding the breakage of the ampoules within their device systems. An extensive investigation revealed that multiple factors have an impact on the ampoule breakage. An unfortunate combination of these influence factors can lead to unbreakable ampoules. If none or not all ampoules break, the product cannot be used on the patient since no or no appropriate cement dough is formed. Lot Code: UDI-DI: 04260102136120; 04260102136151 Distribution: International distribution in the countries of Aland Islands, Australia, Belgium, Denmark, Finland, Germany, Ireland, Italy, Liechtenstein, Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom.
- Hazard
- increase of complaints regarding the breakage of the ampoules within their device systems. An extensive investigation revealed that multiple factors have an impact on the ampoule breakage. An unfortunate combination of these influence factors can lead to unbreakable ampoules. If none or not all ampoules break, the product cannot be used on the patient since no or no appropriate cement dough is formed.
4 products in this recall
PALACOS bone cement recalled for ampoule breakage risk
Heraeus is recalling four PALACOS bone cement products sold in 17 countries outside the US. Some ampoules may not break during mixing, so no usable cement forms and the product cannot be used on a patient. No injuries have been reported.
The agency lists each product separately. Check every one you might have.
- Brand Name: PALACOS Product Name: PALACOS R pro 40; PALACOS R pro 80 Model/Catalog Number: 5081286; 5081287 Software Version: N/A Product Description: Ra… (this page)Z-1080-2026
- Brand Name: PALACOS Product Name: PALACOS R+G pro 40; PALACOS R+G pro 80 Model/Catalog Number: 5081288; 5081289 Software Version: N/A Product Description…Z-1081-2026
- Brand Name: PALACOS Product Name: PALACOS MV+G pro 40; PALACOS MV+G pro 80 Model/Catalog Number: 5081290; 5081291 Software Version: N/A Product Descripti…Z-1082-2026
- Brand Name: PALACOS Product Name: PALACOS MV pro 40; PALACOS MV pro 80 Model/Catalog Number: 5150633; 5150635 Software Version: N/A Product Description:…Z-1083-2026
More from Heraeus
- Heraeus Medical PALACOS R pro bone cement recalled for monomer liquid leakage risk
ModerateFDAOct 7, 2026